Chinese Expert Consensus on Perioperative Medication in Laser Corneal Refractive Surgeries (2024)

Abstract

Laser corneal refractive surgery was first introduced in China over 30 years ago and has become an important treatment for ametropia in recent years, with the number of surgeries performed increasing continuously. Despite its proven safety, efficacy, and stability, refractive surgery-related complications still occur. Rational medication in the perioperative period is essential to ensure the success of surgery and reduce complications. In 2019, experts in the Refractive Surgery Group of the Ocular Microcirculation Branch of the Chinese Society of Microcirculation, specializing in keratology and optometry, published the first edition of the Chinese Expert Consensus on Perioperative Medication in Laser Corneal Refractive Surgeries. The consensus was based on extensive studies of current practices in corneal refractive surgeries domestically and received nationwide attention and acceptance. To accommodate new surgical methods and techniques developed in the past years, experts in the Refractive Surgery Group conducted extensive discussions, updated the consensus on the appropriate perioperative medication regimen for corneal refractive surgeries, and provided recommendations for the prevention and management of adverse reactions and surgical complications. These are presented in the current work.